In a nutshell This study looked at combined treatment with ipilimumab (Yervoy) and nivolumab (Opdivo) for metastatic uveal melanoma (UM). They found that this treatment combination was promising in these patients. Some background Metastatic UM is melanoma that starts in the eye and spreads to other organs. Compared to skin...
Read More
In a nutshell This study looked at the role of circulating tumor DNA (ctDNA) in predicting treatment response in advanced melanoma. They found that in patients treated for the first time with immune treatment, patients with low ctDNA levels had a longer survival without cancer worsening. Some background Advanced melanoma describes melanoma...
Read More
In a nutshell This trial is looking at the effectiveness, safety, and tolerability of ladiratuzumab vedotin (LV) in patients with advanced solid tumors, including melanoma. The main outcome to be measured in this trial is the response rate to the new drug. The details Advanced tumors have spread from the organ where they originated....
Read More
In a nutshell This study looked at patients with melanoma which had spread to the bones. They found that targeted bone treatments can reduce the risk of broken bones and other complications in these patients. Some background Melanoma spreads to the bones in 11-18% of patients. Cancer which has spread to the bone is called bone metastases...
Read More
In a nutshell This study investigated the long-term effectiveness and safety of immunotherapy drug nivolumab (Opdivo) compared to chemotherapy drug dacarbazine (DTIC-Dome) for patients with BRAF-negative advanced melanoma. The study showed that nivolumab significantly increased survival in these...
Read More
In a nutshell This study presents updated longer-term data on recurrence-free survival (RFS) for pembrolizumab (Keytruda) after surgery for stage 3 melanoma. The study showed that pembrolizumab has a lasting and improving effect on RFS as a treatment after surgery. Some background For patients with stage 3 melanoma,...
Read More
In a nutshell This study compared nivolumab (Opdivo) and ipilimumab (Yervoy) for treating advanced melanoma that has been surgically removed. They found that patients treated with nivolumab survived cancer-free for longer than patients treated with ipilimumab. Some background Melanoma which has spread to the lymph nodes or other organs is...
Read More
In a nutshell This study looked at the effects after stopping immune therapy in patients with advanced melanoma. They found that responses to treatment lasted long after treatment was stopped. Some background Stage 3 or 4 melanoma refers to a tumor that has spread to lymph nodes or distant organs. At this advanced stage, the cancer...
Read More
In a nutshell This study was carried out to assess whether immune related side effects (IRSE) of anti-PD1 therapy affect the survival of patients with advanced melanoma. The authors of this study found that patients who had IRSE had better outcomes. Some background Advanced melanoma is a form of skin cancer that comes from a cell called a...
Read More
In a nutshell This study investigated the long-term effectiveness and risks of the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for patients with stage 3 melanoma after tumor removal. It showed that the combination of the two drugs can increase survival without return or spreading of cancer. Some...
Read More
In a nutshell This study was carried out to assess the effectiveness of metastasectomy (ME; surgical removal of tumors that have spread from the original tumor location) for patients with advanced melanoma who responded to targeted or immunotherapy. The authors found that ME for melanoma is associated with a longer overall survival (OS) in...
Read More
In a nutshell This trial is aiming to examine the effectiveness of APG-115 with pembrolizumab (Keytruda) in the treatment of metastatic melanoma. The main outcomes to be measured will be the maximum dose tolerated and the overall response to the drug. This trial is recruiting in multiple locations in the United States. The details...
Read More
